Predictive Oncology (POAI)
(Delayed Data from NSDQ)
$1.12 USD
+0.11 (10.89%)
Updated Jul 12, 2024 04:00 PM ET
After-Market: $1.15 +0.03 (2.68%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
POAI 1.12 +0.11(10.89%)
Will POAI be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for POAI based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for POAI
Senseonics Holdings (SENS) Reports Q1 Loss, Tops Revenue Estimates
American Well Corporation (AMWL) Reports Q1 Loss, Lags Revenue Estimates
POAI: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for POAI
7 F-Rated Growth Stocks to Avoid Right Now: June 2024
Predictive Oncology Develops Novel Stem Cell Expression System for the Production of Functional and Stable G-Protein Coupled Receptors (GPCRs)
Predictive Oncology develops technology designed to express GPCRs
Predictive Oncology Launches Novel 3D Cell Technology to Accelerate Cancer Therapeutic Drug Discovery
Predictive Oncology launches novel 3D cell technology